- Home
- Â /Â Amarin
Amarin
Stock Price
$0.6
2024-10-29
Market Capitalization
$257.6 M
2024-10-29
Revenue
$228.6 M
FY, 2024
Amarin Summary
Company Summary
- Overview
- Amarin Corporation is a pharmaceutical company that engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases. It develops VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
- Type
- Public
- Status
- Active
- Founded
- 1991
- HQ
- Dublin, IE | view all locations
- Website
- https://amarincorp.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jan van Heek, Non-Executive Director
Patrick J. O'Sullivan, Non-Executive Director
Kristine Peterson, Non-Executive Director
Operating MetricsView all
Patents (US)
110
19.6%
FY, 2020
Patent Applications (US)
30
FY, 2020
LocationsView all
3 locations detected
Dublin, DÂ HQ
Ireland
Block C, 77 Sir John Rogerson's Quay
Bridgewater Township, NJ
United States
440 Route 22
Zug, ZG
Switzerland
Grafenauweg 8
Amarin Financials
Summary Financials
- Revenue (FY, 2024)
- $228.6M
- Gross profit (FY, 2024)
- $81.4M
- Net income (FY, 2024)
- ($82.2M)
- Cash (FY, 2024)
- $121.0M
- EBIT (FY, 2024)
- ($91.8M)
- Enterprise value
- $138.5M